A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Rhabdomyosarcoma Clinical Trial

Official title:

A Phase I/II Dose Escalation/Dose Expansion Study of Prexasertib in Combination With Irinotecan in Patients With Relapsed or RefractoryDesmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04095221
• Other study ID #: 19-120
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 17, 2019
• Est. completion date: September 2024

Study information

• Verified date: October 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide. The study will test different doses of prexasertib in combination with irinotecan and temozolomide to find the highest dose of prexasertib that causes few or mild side effects in participants.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months and older

Eligibility

Inclusion Criteria:

• Consent/Assent: all patients and/or their parents or legally authorized representatives must sign written informed consent; assent, when appropriate, will be obtained according to institutional guidelines

• Age: patients must be =12 months of age at the time of study enrollment

• Diagnosis: patients must have histologically documented locally advanced or metastatic desmoplastic small round cell tumor or rhabdomyosarcoma (confirmed at MSK)

• Therapeutic options: patient's current disease state must be one which has failed standard therapy and for which there is no known curative therapy

• Disease Status: patients must have measurable disease based on RECIST 1.1

• Performance level: Karnofsky = 50% for patients > 16 years of age and Lansky = 50 for patients = 16 years of age

• Prior Therapy: patients may have had any number of prior therapies, but must have recovered from the acute toxic effects of all prior anti-cancer therapy (other than alopecia) as described below and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment

°patients who have previously received irinotecan and/or temozolomide will be allowed

• 21 days must have elapsed after the last dose of cytotoxic or myelosuppressive chemotherapy

• 7 days must have elapsed after the last dose of anti-cancer agents not known to be myelosuppressive

• 14 days must have elapsed after radiation therapy, and toxicity related to prior radiation therapy must be recovered to grade = 1

• 21 days must have elapsed after the last dose of antibody therapy, and toxicity related to prior antibody therapy must be recovered to grade = 1

• Organ Function Requirements: Adequate bone marrow function defined as:

• absolute neutrophil count (ANC) = 1500/mm^3

• platelet count = 100,000/ mm^3

• hemoglobin = 8 g/dl

• Adequate renal function defined as:

• Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min/1.73m2 OR

• Serum creatinine based on age/gender derived from the Schwartz formula for estimating GFR53

• Adequate liver function defined as:

• Bilirubin (sum of conjugated + unconjugated) = 1.5 x upper limit of normal for age

• AST or ALT = 5 x upper limit of normal for patients with liver metastases

• Serum albumin = 2.5 g/dl

• Adequate cardiac function defined as:

• echocardiogram with left ventricular ejection fraction (LVEF) >45%

• QTc < 470 ms on screening 12 lead electrocardiogram

• Pregnancy/Contraception

• post-menarchal females must have a negative urine or serum pregnancy test at screening and = 24 hours prior to study treatment

• males or females of reproductive potential must be willing to use a barrier method of contraception throughout the course of the study and for 6 months after participation

Exclusion Criteria:

• Patients for whom the investigator deems that irinotecan and temozolomide are not appropriate are not eligible.

• Patients who have an uncontrolled infection are not eligible.

• Patients who are pregnant or breast feeding are not eligible.

• Patients who have a history of Torsades de Pointes, carry a diagnosis of congestive heart failure, or have a family history of prolonged QT syndrome are not eligible.

• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.

• Patients with known hypersensitivity to irinotecan or its excipients are not eligible.

Related Conditions & MeSH terms

• Desmoplastic Small Round Cell Tumor
• Rhabdomyosarcoma

Intervention

Drug:
• Prexasertib
DOSE LEVELS FOR PATIENTS > 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days DOSE LEVELS FOR PATIENTS = 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days
• Irinotecan
15 mg/m2 IV daily x 10 days in 21 day cycles

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	recommended phase II does of Prexasertib	The RP2D is defined as the highest dose level associated with not more than 1 DLT out of 6 patients. A total of 5 dose levels are planned, including 2 back up levels. The DLT's will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The dose escalation will follow a 3+3 design.	1 year
Primary	response	will be evaluated in this study using the criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1 (Primary response criteria)54. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center